Detecting Gluten Peptides in Human Fluids
AssigneesUniversidad de Sevilla, Biomedal, S.L.
InventorsMaria de Lourdes Moreno Amador, Carolina Sousa Martin, Alfonso Rodriguez Herrera, Angel Cebolla Ramirez
Life of this patent
Estimating the term…
Abstract
The present invention discloses a process for detecting and quantifying gluten peptides resistant to gastrointestinal digestion in human body fluids, preferably urine. The presence or absence of gluten peptides is controlled by immunological assays based on specific gluten peptide antibodies directed thereagainst.
Claims19
1-23. (canceled)
A process for monitoring compliance of a patient with a gluten free diet comprising:
- (a) contacting a urine sample from the patient with a monoclonal antibody selected from the group consisting of G12, R5, and A1 which monoclonal antibody specifically binds gluten immune-toxic peptides having epitopes on any sequence selected from the group consisting of SEQ ID NO:
- 2 and SEQ ID NO:
- 6,
- (b) allowing the monoclonal antibody to form monoclonal antibody-gluten peptide complexes with gluten peptides in the urine sample;
- (c) detecting the monoclonal antibody-gluten peptide complexes formed in step (b);
- (d) quantitating extracted immune-toxic peptides in the urine sample based on detection of monoclonal antibody-gluten peptide complexes;
- and
- (e) repeating steps (a)-(d) and monitoring a level of quantitated immune-toxic peptides determined in step (d), wherein the quantity of the extracted peptides is indicative of a degree of compliance with a gluten free diet.
A method of diagnosing refractory celiac disease, comprising:
- (a) contacting a urine sample from a patient with a monoclonal antibody selected from the group consisting of G12, R5, and A1 which monoclonal antibody specifically binds gluten immune-toxic peptides having epitopes on any sequence selected from the group consisting of SEQ ID NO:
- 2 and SEQ ID NO:
- 6,
- (b) allowing the monoclonal antibody to form monoclonal antibody-gluten peptide complexes with gluten peptides in the urine sample;
- (c) detecting the monoclonal antibody-gluten peptide complexes formed in step (b);
- (d) quantitating extracted immune-toxic peptides in the urine sample based on detection of monoclonal antibody-gluten peptide complexes;
- and
- (e) using the quantitated immune-toxic peptides determined in step (d) as a factor in diagnosing the patient with refractory celiac disease.
A method of diagnosing sensitivity to gluten proteins, comprising:
- (a) contacting a urine sample from a patient with a monoclonal antibody selected from the group consisting of G12, R5, and A1 which monoclonal antibody specifically binds gluten immune-toxic peptides having epitopes on any sequence selected from the group consisting of SEQ ID NO:
- 2 and SEQ ID NO:
- 6,
- (b) allowing the monoclonal antibody to form monoclonal antibody-gluten peptide complexes with gluten peptides in the urine sample;
- (c) detecting the monoclonal antibody-gluten peptide complexes formed in step (b);
- (d) quantitating extracted immune-toxic peptides in the urine sample based on detection of monoclonal antibody-gluten peptide complexes;
- and
- (e) using the quantitated immune-toxic peptides determined in step (d) as a factor in diagnosing the patient with sensitivity to gluten protein.
Dependencies are inferred from the claim text.